Personalized Medicine
166 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Rick Currin
Scoop.it!

Approaches to Targeting Acute and Chronic GVHD

Approaches to Targeting Acute and Chronic GVHD | Personalized Medicine | Scoop.it
Experts review the experience of using new and emerging therapies for treating patients with acute and chronic graft-versus-host disease.
Rick Currin's insight:

Our observation about the immuno-implications of JAK inhibition and IL-6 are on display in Graft versus Host Disease.

 

Quoting:

 

 

"In a retrospective survey of 19 stem cell transplant centers in the United States and Europe, outcomes data from 95 patients who had received ruxolitinib (Jakafi) as salvage therapy for steroid-refractory GVHD showed an overall response rate (ORR) of 81.5% and a complete response (CR) rate of 46.3% for acute GVHD, and an ORR of 85.4% for chronic GVHD. One-year OS in the overall population of 95 patients (acute and chronic GVHD) was 92.7%, and the estimated median OS was not reached."
 
-
more...
No comment yet.
Scooped by Rick Currin
Scoop.it!

The Most Exciting Medical Technologies of 2017 - The Medical Futurist

The Most Exciting Medical Technologies of 2017 - The Medical Futurist | Personalized Medicine | Scoop.it
At this time of every year, I publish my predictions for the coming months. So, here are my thoughts about the top medical technologies of 2017.
Rick Currin's insight:

foundation we avoided as an investment but we remain curious on this one and actually are in the space of liquid biopsy through another name.  Some of these technologies are ready or prime time others not as much.  But we do have a couple of these coming developments covered in investments at currinbiotech.com

more...
No comment yet.
Scooped by Rick Currin
Scoop.it!

‘Liquid biopsies’ could revolutionize cancer detection

‘Liquid biopsies’ could revolutionize cancer detection | Personalized Medicine | Scoop.it
Liquid biopsies, using blood samples instead of tissue samples, hold the promise of detecting the reappearance of cancer much earlier and more accurately.
Rick Currin's insight:

Liquid biopsies may lead to early detection of cancer recurrence or occurrence.   It is the lack of early detection that is so devastating in cancers like pancreatic in particular.  As diagnostic costs continue to come down, the field of personalized medicine and "detection diagnostics" will merge into a powerful force in precision oncology as well as generalized preventative health.  With liquid biopsies the potential for the genomic stethoscope is getting closer to reality.

more...
No comment yet.
Scooped by Rick Currin
Scoop.it!

A 'big win' in Foundation Medicine's quest for coverage of gene tests - Boston Business Journal

A 'big win' in Foundation Medicine's quest for coverage of gene tests - Boston Business Journal | Personalized Medicine | Scoop.it
A decision by one of Medicare's administrative contractors last week could be a turning point in the company's efforts to increase usage of its cancer diagnostics.
Rick Currin's insight:

Roche is certainly committed to the personalized medicine era.  Interestingly most of the drugs in its development pipeline carry a companion diagnostic that defines patient population.

more...
No comment yet.
Scooped by Rick Currin
Scoop.it!

GEN | News Highlights: Roche Acquires License to Nanopore Technology with Sights on $1,000 Whole Genome Sequencing

GEN | News Highlights: Roche Acquires License to Nanopore Technology with Sights on $1,000 Whole Genome Sequencing | Personalized Medicine | Scoop.it
Technology from Biodesign Institute and Columbia University will be used alongside IBM's DNA Transistor platform.
Rick Currin's insight:

A sub-$1000 genome test is considered a magic number for insurers to get on board with personalized medicine and generalized sequencing support.

more...
No comment yet.
Scooped by Rick Currin
Scoop.it!

GENOMIC HEALTH: Interpreting the Oncotype DX GPS Report

Bela Denes, Senior Director of Medical Affairs Urology at Genomic Health, discusses how to interpret the Oncotype DX Prostate Cancer Assay Report.
Rick Currin's insight:

Prostate Cancer is quite common.  The Oncontype report here is highlighted allowing you to understand more about how doctors may choose active surveillance versus more aggressive therapies.  Wait and see approaches are an increasing part of the personalized medicine landscape as they save burden on patients and costs to insurers.

more...
No comment yet.
Scooped by Rick Currin
Scoop.it!

Will “liquid biopsy” replace conventional tissue-based sampling?

Will “liquid biopsy” replace conventional tissue-based sampling? | Personalized Medicine | Scoop.it
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Benjamin Levy queries whether liquid biopsy will replace conventional tissue-based sampling.

Earn CME Credit for a related activity: http://elc.imedex.com/ELC/S...

© 2017 Imedex, LLC.
Rick Currin's insight:

A good albeit long and technical conference discussion.  Liquid biopsy is identifying stage I lung cancer patients.  The implications of early detection using the technology are quite underestimated in my opinion.

more...
No comment yet.
Scooped by Rick Currin
Scoop.it!

With $40M in Financing, Epic Sciences to Advance Liquid Biopsy Cancer Tests | Articles | ClinicalOMICs

With $40M in Financing, Epic Sciences to Advance Liquid Biopsy Cancer Tests | Articles | ClinicalOMICs | Personalized Medicine | Scoop.it
Company also plans to enhance its proprietary No Cell Left Behind technology to include characterization of rare leukocyte cell populations. Read more at www.ClinicalOMICS.com.
Rick Currin's insight:

This is a market push through advantage....

 

"These data show that patients with detectable levels of AR-V7 positive circulating tumor cells in their blood had significantly better clinical outcomes when treated with taxane chemotherapy than more expensive targeted therapies."

 

Insurers should love the application because of this.

 

Epic is securing a good amount of capital infusion including the investment via Genomic Health.  Keeping an eye on this one.

more...
No comment yet.
Scooped by Rick Currin
Scoop.it!

Looking Ahead: Precision Immunology in Cancer | Rutgers Cancer Institute of New Jersey

Looking Ahead: Precision Immunology in Cancer | Rutgers Cancer Institute of New Jersey | Personalized Medicine | Scoop.it
Rick Currin's insight:

We are now in exciting times as the potential for precision or personalized approaches seeks to meet up with the promise of durable remissions starting to be delivered with immunotherapy.

more...
No comment yet.
Scooped by Rick Currin
Scoop.it!

Personalized Medicine Has Friends in High Places - Currin Biotech Investment Newsletter

Personalized Medicine Has Friends in High Places - Currin Biotech Investment Newsletter | Personalized Medicine | Scoop.it
Biotechnology Stocks for High Returns! – Investment newsletter focused on life science and biotech stocks. Get the research and insights you need to invest in personalized medicine, cancer’s Achilles’ heel, cancer stem cells, and the future of medicine.
Rick Currin's insight:

It's good to see the NIH personalized medicine slide used in POTUS's PowerPoint presentation.  The President calls it precision medicine as he announced a “precision medicine initiative to bring us closer to curing diseases like cancer and diabetes and to give all of us access to the personalized information that we need to keep ourselves and our families healthy”.

more...
Scooped by Rick Currin
Scoop.it!

EZH2 HMT animation - YouTube

Rick Currin's insight:

EZP-6438 has positive results in Phase I.  Four of ten evaluable patients with relapsed non-Hodgkin’s Lymphoma had partial response or better.  One complete response was also achieved in this set. One of two patients with INI1 deficient rhaboid, as discussed in this video, saw positive response as well.  Safety also looks promising.

more...
No comment yet.
Scooped by Rick Currin
Scoop.it!

Personalized Medicine through the Genome - Currin Biotech Investment Newsletter

Personalized Medicine through the Genome - Currin Biotech Investment Newsletter | Personalized Medicine | Scoop.it
Biotechnology Stocks for High Returns! – Investment newsletter focused on life science and biotech stocks. Get the research and insights you need to invest in personalized medicine, cancer’s Achilles’ heel, cancer stem cells, and the future of medicine.
Rick Currin's insight:

The right drug for the right disease in the right patient opens up investments in the biotech / life science space somewhat free of the perils and pitfalls of clinical trials.

more...
No comment yet.